GlassScriptPhysician profile
Shalini Krishnasamy
NPI 1154858314
$2,829.03
in general payments reported to CMS, 2019-2025
11 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $400 · 2022: $707 · 2023: $675 · 2024: $873 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,540 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,539.78 |
| Education | $182.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $583.57 | 2022-2024 | Tremfya |
| Janssen Scientific Affairs, LLC | $483.99 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $465.08 | 2023-2025 | |
| Abbvie INC. | $261.88 | 2022 | |
| Dermavant Sciences, INC. | $242.73 | 2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $233.10 | 2023 | Dupixent |
| Pfizer INC. | $205.62 | 2024-2025 | |
| Amgen INC. | $140.80 | 2024 | Otezla |
| Genzyme Corporation | $136.20 | 2021 | |
| Galderma Laboratories, L.P. | $52.95 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $23.11 | 2023 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shalini Krishnasamy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.